Massachusetts Financial Services Co. MA Sells 89,591 Shares of Cencora, Inc. $COR

Key Points

• Massachusetts Financial Services cut its Cencora stake by 13.6%, selling 89,591 shares and ending the quarter with 568,119 shares worth about $191.88 million (≈0.29% of the company).
• Cencora beat Q4 EPS at $4.08 versus the $4.04 estimate while revenue was $85.93 billion (slightly below expectations) and up 5.5% year-over-year; the stock has a $62.44B market cap, a P/E of 38.58, and pays a $0.60 quarterly dividend (≈0.7% yield).
• Analysts remain largely positive—several firms raised targets (Wells Fargo to $429, Barclays to $425), with an average price target of $398.17 and 12 Buys versus 2 Holds.

Massachusetts Financial Services Co. MA lowered its holdings in Cencora, Inc. (NYSE:COR - Free Report) by 13.6% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 568,119 shares of the company's stock after selling 89,591 shares during the period. Massachusetts Financial Services Co. MA owned approximately 0.29% of Cencora worth $191,882,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of the business. IAG Wealth Partners LLC bought a new stake in shares of Cencora during the 3rd quarter worth approximately $30,000. Cloud Capital Management LLC bought a new position in Cencora in the 3rd quarter valued at approximately $31,000. Caitlin John LLC bought a new position in Cencora in the 3rd quarter valued at approximately $31,000. Westside Investment Management Inc. lifted its stake in Cencora by 200.0% in the 3rd quarter. Westside Investment Management Inc. now owns 105 shares of the company's stock valued at $33,000 after purchasing an additional 70 shares during the last quarter. Finally, Harbor Investment Advisory LLC bought a new position in Cencora in the 4th quarter valued at approximately $35,000. Institutional investors own 97.52% of the company's stock.

Cencora Trading Up 0.0%

Shares of NYSE COR opened at $320.97 on Monday. The company has a debt-to-equity ratio of 3.62, a quick ratio of 0.51 and a current ratio of 0.92. Cencora, Inc. has a 52-week low of $271.00 and a 52-week high of $377.54. The firm has a 50 day moving average price of $345.36 and a two-hundred day moving average price of $342.83. The stock has a market cap of $62.44 billion, a P/E ratio of 38.58, a price-to-earnings-growth ratio of 1.50 and a beta of 0.72.

Cencora (NYSE:COR - Get Free Report) last announced its quarterly earnings results on Wednesday, February 4th. The company reported $4.08 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.04 by $0.04. Cencora had a net margin of 0.50% and a return on equity of 176.54%. The firm had revenue of $85.93 billion during the quarter, compared to analysts' expectations of $86.12 billion. During the same period in the prior year, the company posted $3.73 EPS. The company's revenue was up 5.5% on a year-over-year basis. As a group, equities analysts forecast that Cencora, Inc. will post 15.37 EPS for the current year.

Cencora Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, March 2nd. Shareholders of record on Friday, February 13th were given a $0.60 dividend. This represents a $2.40 annualized dividend and a yield of 0.7%. The ex-dividend date was Friday, February 13th. Cencora's dividend payout ratio is 28.85%.

Insider Transactions at Cencora

In other Cencora news, CEO Robert P. Mauch sold 5,096 shares of the company's stock in a transaction that occurred on Tuesday, January 20th. The shares were sold at an average price of $354.73, for a total value of $1,807,704.08. Following the completion of the transaction, the chief executive officer directly owned 66,726 shares in the company, valued at approximately $23,669,713.98. This represents a 7.10% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 0.38% of the company's stock.

Analysts Set New Price Targets

Several brokerages recently commented on COR. Wells Fargo & Company increased their price objective on shares of Cencora from $405.00 to $429.00 and gave the company an "overweight" rating in a research note on Tuesday, February 10th. Robert W. Baird set a $415.00 price objective on shares of Cencora in a research note on Tuesday, January 13th. Barclays increased their price objective on shares of Cencora from $400.00 to $425.00 and gave the company an "overweight" rating in a research note on Friday, February 13th. Evercore set a $360.00 price objective on shares of Cencora in a research note on Wednesday. Finally, Leerink Partners reissued an "outperform" rating on shares of Cencora in a research note on Tuesday, March 17th. Twelve analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $398.17.

Cencora Profile

Cencora NYSE: COR is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company's core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.